Thermo Fisher to divest microbiology unit to Astorg for $1.075 billion; Ligand announces purchase of XOMA

Thermo Fisher Scientific announced it will sell its microbiology business, part of its specialty diagnostics segment, to European private‑equity firm Astorg.

The transaction is valued at $1.075 billion, reflecting Thermo Fisher's strategic focus on other core areas.

In a separate move, biotech company Ligand indicated it will acquire XOMA, though financial terms were not disclosed.

Both deals illustrate ongoing consolidation in the life‑science and biotech sectors as companies reposition their portfolios.